Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Globe Newswire•09/11/2026•16:05 ET
2
Key Highlights
- ➤$1.2 billion cash expected to fund operations and key clinical milestones through 2028
- ➤Phase 3 ACCOMPLISH trials enrolling, with topline data expected in 2H 2028
- ➤Q3 R&D expenses $134.6 million, up from $59.0 million year over year
- ➤Q3 net loss $144.8 million, versus $65.7 million in 2025
- ➤ACCG-2671 showed approximately six-day half-life with no serious adverse events
Expert Statements
Raymond Stevens, Chief Executive Officer of Structure Therapeutics
“With our Phase 3 ACCOMPLISH program underway, we are advancing aleniglipron toward potential registration while building a broader portfolio of differentiated oral small molecule treatments for chronic weight management.”
Raymond Stevens, Chief Executive Officer of Structure Therapeutics
“We are developing our commercial readiness plans and see significant opportunity for aleniglipron in both initial weight loss and long-term weight loss maintenance.”
Raymond Stevens, Chief Executive Officer of Structure Therapeutics
“We are also advancing our oral small molecule amylin portfolio by progressing the multiple ascending dose clinical trial of ACCG-2671, preparing to initiate a Phase 1 clinical trial of ACCG-3535 and exploring GLP-1 combination approaches.”
Raymond Stevens, Chief Executive Officer of Structure Therapeutics
“Our strategy is to develop differentiated monotherapy and combination medicines to address a range of patient needs.”
Raymond Stevens, Chief Executive Officer of Structure Therapeutics
“We believe convenient oral administration and scalable manufacturing could help expand access to these potential treatments globally.”
Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028
Additional aleniglipron data expected in Q4 2026 from supplementary body composition, type 2 diabetes and SWITCH studies
Get started
Create a free account to read the full story.